Follow us on Twitter
twitter icon@FreshPatents


Erythropoietin patents

      

This page is updated frequently with new Erythropoietin-related patent applications.




 Purification of erythropoietin patent thumbnailPurification of erythropoietin
In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing calcium-ions and namely under conditions under which the erythropoietin binds to the stationary phase containing hydroxyapatite, ii) a solution is passed over the stationary phase containing hydroxyapatite from i) which contains less calcium-ions than the previous solution and the erythropoietin is not detached from stationary phase containing hydroxyapatite, and iii) a further solution which contains less than 0.5 mm calcium-ions is passed over the stationary phase containing hydroxyapatite from ii) whereby the erythropoietin is detached from the stationary phase containing hydroxyapatite..
F. Hoffmann-la Roche Ag


 Vectors conditionally expressing protein patent thumbnailVectors conditionally expressing protein
This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.
Intrexon Corporation


 Conjugate comprising erythropoietin and a branched polymer structure patent thumbnailConjugate comprising erythropoietin and a branched polymer structure
The present invention discloses a conjugate comprising erythropoietin (epo) and an asymmetric branched polymeric structure comprising two branches of monomethoxypolyethylene glycol (mpeg), where the molecular mass of one of these mpeg branches is between 10 kda and 14 kda, and the molecular mass of the other branch of mpeg is between 17 kda and 23 kda, as well as the pharmaceutical compositions containing it. The invention also provides a method for the preparation of pegylated epo, wherein said protein is conjugated to an asymmetric branched polymeric structure with two branches of mpeg having the above described molecular masses..
Centro De Inmunologia Molecular


 Pharmaceutical composition comprising erythropoietin and ceftriaxone and a  treating parkinson's disease dementia patent thumbnailPharmaceutical composition comprising erythropoietin and ceftriaxone and a treating parkinson's disease dementia
The invention discloses a pharmaceutical composition for treating parkinson's disease dementia (pdd), which including erythropoietin and ceftriaxone. The invention also discloses a use of the pharmaceutical composition in the manufacture of a medicament for the treatment of pdd..
Raygene Biotech International Inc.


 Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides patent thumbnailMethods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides
The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (epo)-derived oligopeptides.. .

 Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients patent thumbnailMethods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients
The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (esa) comprising administering soluble ferric triphosphate (sfp) composition and administering a dose of esa that is significantly reduced compared to the dose of esa required by a dialysis patient that is hyporesponsive to esa that has not received sfp.. .
Rockwell Medical, Inc.


 Tissue protective peptides and uses thereof patent thumbnailTissue protective peptides and uses thereof
The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
Araim Pharmaceuticals, Inc.


 Isolated renal cells and uses thereof patent thumbnailIsolated renal cells and uses thereof
The invention is directed to isolated renal cells, including tubular and erythropoietin (epo)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.. .
Regenmedtx, Llc


 Compositions and methods for increasing erythropoietin (epo) production patent thumbnailCompositions and methods for increasing erythropoietin (epo) production
The invention relates to double-stranded ribonucleic acid (dsrna) compositions targeting one or more egln genes, egln1, egln2 and/or egln3 and methods of using such dsrna compositions to inhibit expression of these genes.. .

 Recombinant protein patent thumbnailRecombinant protein
A recombinant protein is provided. The recombinant protein of the invention comprises an erythropoietin and a highly glycosylated peptide, and has a longer half-life.

Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent

Wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin..

Derivatisation of erythropoietin (epo)

The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Lipoxen Technologies Limited

Derivatisation of erythropoietin (epo)

The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Lipoxen Technologies Limited

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of prostatic acid phosphatase, lactotransferrin, soluble erythropoietin receptor, von willebrand factor, soluble endothelial protein c receptor, and beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.

Compounds and methods for enhancing erythropoiesis

Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (i) indicated below, in which r is a glucosyl group.

Organoids comprising isolated renal cells and use thereof

Described herein are organoids comprising admixtures of selected bioactive primary renal cells and a bioactive cell population, e.g., an endothelial cell populations, e.g. Huvec cells, and methods of treating a subject in need thereof with such organoids.

Novel feline erythropoietin receptor agonists

The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.. .
Askgene Pharma, Inc.

Long lasting drug formulations

The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.. .
Medgenics Medical Israel Ltd.

Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of erythropoietin and about 100-300 mg per cm2 wound tissue of fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject.
Remedor Biomed Ltd.

Modified animal erythropoietin polypeptides and their uses

Modified animal erythropoietin polypeptides and uses thereof are provided.. .
Eli Lilly And Company

Enhanced liquid formulation stability of erythropoietin alpha through purification processing

A method for purifying rhuepo through the use of a multi-step filtration process which provides for a rhuepo product having superior stability and shelf-life.. .
Apotex Inc.

Composition and inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell

A composition for inducing erythropoietin (epo)-mediated haemoglobin (hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (i), wherein r is a glycosyl group; and a pharmaceutical acceptable carrier..
National Yang-ming University

Selective cell therapy for the treatment of renal failure

Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (epo).
Wake Forest University Health Sciences



Erythropoietin topics:
  • Erythropoietin
  • Red Blood Cell
  • Recombinant
  • Nucleic Acid
  • Genetically
  • Regulatory Sequence
  • Endogenous
  • Peptide Sequence
  • Carbamylated
  • Ischemic Stroke
  • Therapeutical
  • Intracranial
  • Thrombopoietin
  • Leukemia Inhibitory Factor
  • Somatostatin


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Erythropoietin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Erythropoietin with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.5835

    file did exist - 2558

    1 - 1 - 51